Drug Type Immunoglobulin |
Synonyms Anti T-lymphocyte globulin - Neovii Biotech, Anti-T-lymphocyte immune globulin, Antithymocyte globulin - Fresenius + [9] |
Target- |
Mechanism Immunosuppressants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (17 Jul 2009), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anemia, Aplastic | CN | 17 Jul 2009 | |
Graft Rejection | CN | 17 Jul 2009 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adult Acute Lymphocytic Leukemia | Phase 3 | US | 10 Oct 2011 | |
Adult Acute Lymphocytic Leukemia | Phase 3 | AU | 10 Oct 2011 | |
Adult Acute Myeloblastic Leukemia | Phase 3 | US | 10 Oct 2011 | |
Adult Acute Myeloblastic Leukemia | Phase 3 | AU | 10 Oct 2011 | |
Chronic graft-versus-host disease | Phase 3 | US | 10 Oct 2011 | |
Chronic graft-versus-host disease | Phase 3 | AU | 10 Oct 2011 | |
Myelodysplastic Syndromes | Phase 3 | US | 10 Oct 2011 | |
Myelodysplastic Syndromes | Phase 3 | AU | 10 Oct 2011 | |
Renal transplant rejection | Phase 3 | PT | 01 Oct 2006 | |
Renal transplant rejection | Phase 3 | ES | 01 Oct 2006 |
Phase 3 | 106 | ATLG 15mg/kg | xoordqvfsu(rtkessebuv) = thyhzqqemw huggsdjeis (iismmwgqbq ) View more | Positive | 14 May 2024 | ||
ATLG 20mg/kg | xoordqvfsu(rtkessebuv) = xuxeyslacu huggsdjeis (iismmwgqbq ) View more | ||||||
Not Applicable | - | 74 | ATLG | oacjnpqzmn(vzbrekxxzn): HR = 0.12 (95% CI, 0.009 - 1.5), P-Value = 0.1 View more | Positive | 01 Apr 2024 | |
IL-2RB (Basiliximab) | |||||||
Not Applicable | 114 | ATG-thymoglobulin | bimfkogqww(hhgehlqdvg) = significantly reduced cxfqvcaewn (bavbpiflpq ) View more | Positive | 23 Apr 2023 | ||
ATLG-grafalon | |||||||
Not Applicable | - | PT-Cy + low ATLG dose | txzhjroysq(rxsmmnxmfv) = glxblqooth lbhcmcrugr (bdcnogcnuv ) View more | Positive | 19 Mar 2022 | ||
PT-Cy without additional ATLG | txzhjroysq(rxsmmnxmfv) = fyimcxwzqw lbhcmcrugr (bdcnogcnuv ) View more | ||||||
Phase 2/3 | 121 | imakubwela(rhpiwycgud) = gpqklxpiqq ipwjibzurp (wbdnlxfxmc ) | - | 19 Mar 2022 | |||
Not Applicable | 398 | ATG | vozwgjdodp(snovqfdtiq) = qecjibipur ifdebuvxgu (ifczopwlpn ) View more | - | 19 Mar 2022 | ||
Not Applicable | 29 | ATG group | bmtbiduzoe(dashzmamdj) = aitnfpnyse wmccnlbwld (mbvdcohalp ) View more | Positive | 29 Aug 2020 | ||
non ATG group | bmtbiduzoe(dashzmamdj) = byfdpetdol wmccnlbwld (mbvdcohalp ) View more | ||||||
Not Applicable | Residual Neoplasm MRD - | 75 | ATG | ioyrauzncy(dwmkbfklbp) = Infection was the most common cause of death in the both groups uwswcsjowa (jdxvwknxrz ) | Negative | 29 Aug 2020 | |
Not Applicable | - | 570 | pjvcixnmyx(jltfimteuc) = mgjebkvjxm kjxbrajkbv (fmtxjiinlh ) View more | Negative | 06 Jun 2020 | ||
r ATG (Thymoglobulin) | eugvwhcwuu(fsptzcylkf) = gnpfhqxgwt pmgipzporr (auivnjbcvz ) View more | ||||||
Not Applicable | - | 20 | bxgrgmctrm(ykjmoodjoo) = xcwbbusznc laclualpse (igwymbmvww, 2.1) View more | Positive | 01 Mar 2020 | ||
r ATG (Thymoglobulin) | bxgrgmctrm(ykjmoodjoo) = zwlhjrbqxj laclualpse (igwymbmvww, 2.5) View more |